verapamil and ziprasidone

verapamil has been researched along with ziprasidone in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (50.00)29.6817
2010's7 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M1
Li, J; Rajamani, R; Reynolds, CH; Tounge, BA1
Nagashima, R; Nishikawa, T; Tobita, M1
Lombardo, F; Obach, RS; Waters, NJ1
Jia, L; Sun, H1
Caron, G; Ermondi, G; Visentin, S1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Campillo, NE; Guerra, A; Páez, JA1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Sen, S; Sinha, N1
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K1
Peters, JU1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dang, NL; Hughes, TB; Miller, GP; Swamidass, SJ1

Reviews

2 review(s) available for verapamil and ziprasidone

ArticleYear
Polypharmacology - foe or friend?
    Journal of medicinal chemistry, 2013, Nov-27, Volume: 56, Issue:22

    Topics: Animals; Communicable Diseases; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Polypharmacology; Safety

2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

12 other study(ies) available for verapamil and ziprasidone

ArticleYear
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
    Journal of medicinal chemistry, 2002, Aug-29, Volume: 45, Issue:18

    Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship

2002
A two-state homology model of the hERG K+ channel: application to ligand binding.
    Bioorganic & medicinal chemistry letters, 2005, Mar-15, Volume: 15, Issue:6

    Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation

2005
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
    Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11

    Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated

2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Support vector machines classification of hERG liabilities based on atom types.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve

2008
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:5

    Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship

2009
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:3

    Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:2

    Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship

2011
QSAR-based permeability model for drug-like compounds.
    Bioorganic & medicinal chemistry, 2011, Apr-15, Volume: 19, Issue:8

    Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2011
Computationally Assessing the Bioactivation of Drugs by N-Dealkylation.
    Chemical research in toxicology, 2018, 02-19, Volume: 31, Issue:2

    Topics: Aldehydes; Amines; Dealkylation; Humans; Indinavir; Liver; Microsomes, Liver; Models, Molecular; Molecular Structure; Piperacillin; Piperazines; Thiazoles; Verapamil

2018